Intended for healthcare professionals

Letters Hormone replacement therapy and venous thromboembolism

Postmenopausal hormone therapy and risk of venous thromboembolism: what about progesterone?

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l601 (Published 11 February 2019) Cite this as: BMJ 2019;364:l601
  1. Pierre-Yves Scarabin, emeritus research director
  1. Inserm U1018, Hôpital Paul Brousse, 94807 Villejuif, France
  1. pierre-yves.scarabin{at}inserm.fr

The UK study by Vinogradova and colleagues provides further evidence that oral but not transdermal oestrogen is associated with increased risk of venous thromboembolism among women who use postmenopausal hormone therapy.1 Previous studies have shown this safety advantage of transdermal oestrogen, together with the important role of concomitant progestogens.23

Progesterone is …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription